Skip to content

Effects of DLX-001 on PD, Safety, Tolerability, and PK in Participants with MDD

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-517139-29-00
Acronym
DLX-001-102
Enrollment
20
Registered
2024-11-04
Start date
2024-11-06
Completion date
2025-06-05
Last updated
2025-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder (MDD)

Interventions

None listed

Sponsors

Delix Therapeutics Inc., Delix Therapeutics Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026